MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Cytokinetics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

37.5 -6.67

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

37.32

Max

40.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

11M

-150M

Pardavimai

16M

17M

Pelnas, tenkantis vienai akcijai

-1.26

Pelno marža

-886.276

Darbuotojai

498

EBITDA

13M

-125M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+102.61% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-723M

5.1B

Ankstesnė atidarymo kaina

44.17

Ankstesnė uždarymo kaina

37.5

Naujienos nuotaikos

By Acuity

75%

25%

342 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Cytokinetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-06-05 15:26; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Akcijų palyginimas

Kainos pokytis

Cytokinetics Inc Prognozė

Kainos tikslas

By TipRanks

102.61% į viršų

12 mėnesių prognozė

Vidutinis 81.43 USD  102.61%

Aukščiausias 120 USD

Žemiausias 62 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cytokinetics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

15

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 42.705Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

342 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.